Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,016 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Is this the time to introduce minimal residual disease in multiple myeloma clinical practice?
Paiva B, Puig N, García-Sanz R, San Miguel JF; Grupo Español de Mieloma (GEM)/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (PETHEMA) cooperative study groups. Paiva B, et al. Clin Cancer Res. 2015 May 1;21(9):2001-8. doi: 10.1158/1078-0432.CCR-14-2841. Epub 2015 Mar 9. Clin Cancer Res. 2015. PMID: 25754350 Review.
V. Smoldering multiple myeloma.
Mateos MV, San Miguel J. Mateos MV, et al. Hematol Oncol. 2015 Jun;33 Suppl 1:33-7. doi: 10.1002/hon.2213. Hematol Oncol. 2015. PMID: 26062051 Review. No abstract available.
Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.
Martínez-López J, Paiva B, López-Anglada L, Mateos MV, Cedena T, Vidríales MB, Sáez-Gómez MA, Contreras T, Oriol A, Rapado I, Teruel AI, Cordón L, Blanchard MJ, Bengoechea E, Palomera L, de Arriba F, Cueto-Felgueroso C, Orfao A, Bladé J, San Miguel JF, Lahuerta JJ; Spanish Multiple Myeloma Group / Program for the Study of Malignant Blood Diseases Therapeutics (GEM / PETHEMA) Cooperative Study Group. Martínez-López J, et al. Blood. 2015 Aug 13;126(7):858-62. doi: 10.1182/blood-2015-04-638742. Epub 2015 Jun 18. Blood. 2015. PMID: 26089396 Free PMC article. Clinical Trial.
Multiple Myeloma Minimal Residual Disease.
Paiva B, García-Sanz R, San Miguel JF. Paiva B, et al. Cancer Treat Res. 2016;169:103-122. doi: 10.1007/978-3-319-40320-5_7. Cancer Treat Res. 2016. PMID: 27696260 Review.
Origin of Waldenstrom's macroglobulinaemia.
García-Sanz R, Jiménez C, Puig N, Paiva B, Gutiérrez NC, Rodríguez-Otero P, Almeida J, San Miguel J, Orfão A, González M, Pérez-Andrés M. García-Sanz R, et al. Best Pract Res Clin Haematol. 2016 Jun;29(2):136-147. doi: 10.1016/j.beha.2016.08.024. Epub 2016 Oct 6. Best Pract Res Clin Haematol. 2016. PMID: 27825459 Review.
Is immunotherapy here to stay in multiple myeloma?
Rodríguez-Otero P, Paiva B, Engelhardt M, Prósper F, San Miguel JF. Rodríguez-Otero P, et al. Haematologica. 2017 Mar;102(3):423-432. doi: 10.3324/haematol.2016.152504. Epub 2017 Jan 12. Haematologica. 2017. PMID: 28082344 Free PMC article. Review.
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group.
Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos MA, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E. Cavo M, et al. Lancet Oncol. 2017 Apr;18(4):e206-e217. doi: 10.1016/S1470-2045(17)30189-4. Lancet Oncol. 2017. PMID: 28368259 Review.
1,016 results